Max Chat
Calendrier des promotions PolyPid Ltd.
Calendrier avancé
Graphique simple
À propos de l'entreprise PolyPid Ltd.
PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.Paramètres de base
IPO date
2020-06-26
ISIN
IL0011326795
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 0 | 0 |
| P/BV | 2.34 | 6 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -142.99 | 0 |
| ROE | -1038.73 | 0 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | -0.3723 | 10 |
| Debt/Ratio | 0.3813 | 10 |
| Debt/Equity | 2.28 | 6 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 0 | 0 |
| Rentabilité Ebitda, % | -1.78 | 0 |
| Rentabilité EPS, % | 33.02 | 5 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 3.41 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 3.46 $ | 0 $ | 0 $ | -1.45 % | 0 % | 0 % |
| common.calendar.number_days.30d | 2.78 $ | 3.41 $ | 3.41 $ | +22.66 % | 0 % | 0 % |
| common.calendar.number_days.90d | 2.48 $ | 2.52 $ | 3.5 $ | +37.5 % | 0 % | 0 % |
| common.calendar.number_days.180d | 3.06 $ | 2.4 $ | 3.5 $ | +11.44 % | 0 % | 0 % |
| common.calendar.number_days.1y | 3.5 $ | 2.4 $ | 3.76 $ | -2.57 % | 0 % | 0 % |
| common.calendar.number_days.3y | 6.26 $ | 0.2805 $ | 9.27 $ | -45.53 % | 0 % | 0 % |
| common.calendar.number_days.5y | 13.9 $ | 0.2805 $ | 16.9 $ | -75.47 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0.2805 $ | 0.2805 $ | 19 $ | +1 215.69 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 2.98 $ | 2.4 $ | 3.5 $ | +14.43 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Ms. Dikla Czaczkes Akselbrad | CEO & Director | 347.88k | 1973 (52 année) |
| Ms. Dalit Hazan | Deputy CEO and Executive VP of R&D, Clinical & Regulatory Affairs | 272.38k | 1971 (54 année) |
| Mr. Ori Warshavsky | Chief Operating Officer - US | 340.89k | 1978 (47 années) |
| Mr. Jonny Missulawin | Chief Financial Officer | 186.96k | 1987 (38 années) |
| Ms. Maria Rubin | Vice President of Operations | N/A | |
| Mr. Tal Vilnai | General Counsel & Corporate Secretary | N/A | |
| Ms. Rivi Lev-ari | Vice President of Human Resource | N/A | |
| Dr. Jean-Marc Hagai Pharm.D. | Chief Commercial Officer | N/A |
Informations sur l'entreprise
Adresse: Israel, Petah Tikva, 18 Hasivim Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.polypid.com
Site web: https://www.polypid.com
